BioWednesday: How Ready Are We for Advanced Therapies?

Advanced therapeutics refer to medicines based on genes, tissues and cells. They offer new opportunities for treatments in areas of high un-met needs.

In order to adopt these medicines into standard healthcare, there needs to be consideration of the differences to pharmaceuticals and biologics and the significantly more complicated supply chain that they require. This includes challenges around shelf-life of therapies, manufacturing close to treatment, feasibility of large batches and reducing costs, to name but a few.

Our BioWednesday will look at the manufacturing challenges that we need to tackle in order to deliver advanced therapies to patients. It will feature examples of excellence that are helping to scale-up manufacturing  and ultimately help to implement these therapies in the long term for greater numbers of patients.

Programme:
11.30 Registration and networking over tea and coffee
12.00 Welcome from hosts
Alicia Gailliez, Business Development Manager, One Nucleus
Wesley Randle, Chief Business Officer, Stevenage Bioscience Catalyst
12.10 Presentations from Manufacturers and Therapeutics Organisations on how they’re accelerating cell and gene therapies
Speakers include:
     • Matthew Miell, Viral Vector Group Leader, GE Healthcare
     • Sharon Brownlow, Head of Collaborations - Manufacturing Centre, Cell & Gene Therapy Catapult
     • Dara Henry, VP Operations and Business Development, Achilles Therapeutics Ltd
13.15 Lunch / Round table discussions with presenting organisations
14.15 End

Prices
One Nucleus Members: Free
Non-Members: £50 +VAT
Academics: please contact Alicia 

**This button will not work if you are not logged in**